Mechanisms of homocysteine-induced glomerular injury and sclerosis

American Journal of Nephrology

Volumn 28, Issue 2, 2008, Pages 254-264

  Yi, Fan ^a   Li, Pin Lan ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glomerulus; Hyperhomocysteinemia; Mesangial cells; Oxidative stress; Podocytes; Proteinuria; Sulfur amino acids

Indexed keywords

CREATININE; HOMOCYSTEINE; REACTIVE OXYGEN METABOLITE;

AMINO ACID METABOLISM; CACHEXIA; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEALTH HAZARD; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPOALBUMINEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY INJURY; MALNUTRITION; META ANALYSIS; METHYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STROKE; SYSTEMATIC REVIEW;

ANIMALS; ENDOPLASMIC RETICULUM; HOMOCYSTEINE; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; METHYLATION; MITOCHONDRIA; MODELS, BIOLOGICAL; OXIDATIVE STRESS; OXYGEN; REACTIVE OXYGEN SPECIES; SCLEROSIS;

EID: 38349003348     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110876     Document Type: Review

References (67)

1. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR: Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-1232.
2. Cavalca V, Cighetti G, Bamonti F, Loaldi A, Bortone L, Novembrino C, De Franceschi M, Belardinelli R, Guazzi MD: Oxidative stress and homocysteine in coronary artery disease. Clin Chem 2001;47:887-892.
3. Perry IJ: Homocysteine, hypertension and stroke. J Hum Hypertens 1999;13:289-293.
4. Yoo JH, Lee SC: Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001;158:425-430.
5. 12, folate, homocysteine, and creatinine in predicting outcomes in heart transplant recipients. Am J Cardiol 2002;89:834-837.
6. Mills JL, Scott JM, Kirke PN, McPartlin JM, Conley MR, Weir DG, Molloy AM, Lee YJ: Homocysteine and neural tube defects. J Nutr 1996;126:756S-760S.
7. Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H: Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2002;58:1539-1541.
8. Dennis VW, Robinson K: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl 1996;57:S11-S17.
9. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM: Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000;11:134-137.
10. Gupta A, Robinson K: Hyperhomocysteinaemia and end-stage renal disease. J Nephrol 1997;10:77-84.
11. Guttormsen AB, Ueland PM, Svarstad E, Refsum H: Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997;52:495-502.
12. Perna AF, Ingrosso D, Satta E, Lombardi C, Acanfora F, De Santo NG: Homocysteine metabolism in renal failure. Curr Opin Clin Nutr Metab Care 2004;7:53-57.
13. Brosnan JT, Jacobs RL, Stead LM, Brosnan ME: Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol 2004;51:405-413.
14. Li N, Chen L, Muh RW, Li PL: Hyperhomocysteinemia associated with decreased renal transsulfuration activity in Dahl S rats. Hypertension 2006;47:1094-1100.
15. van Guldener C, Stam F, Stehouwer CD: Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation. Clin Chem Lab Med 2005;43:1026-1031.
16. Jacobsen DW: Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998;44:1833-1843.
17. Kang SS, Wong PW, Malinow MR: Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-298.
18. Perna AF, Capasso R, Lombardi C, Acanfora F, Satta E, Ingrosso D: Hyperhomocysteinemia and macromolecule modifications in uremic patients. Clin Chem Lab Med 2005;43:1032-1038.
19. Refsum H, Ueland PM, Nygard O, Vollset SE: Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
20. McCully KS, Wilson RB: Homocysteine theory of arteriosclerosis. Atherosclerosis 1975;22:215-227.
21. McCully KS: Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med 2005;43:980-986.
22. McCully KS: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
23. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A: Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992;22:214-221.
24. Malinow MR, Levenson J, Giral P, Nieto FJ, Razavian M, Segond P, Simon A: Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995;114:175-183.
25. Boers GH: Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost 2000;26:291-295.
26. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
27. Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
28. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.
29. Brattström L, Wilcken DE: Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72:315-323.
30. Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM: Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 1998;18:535-541.
31. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20.
32. Perna AF, Ingrosso D, Castaldo P, De Santo NG, Galletti P, Zappia V: Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. Miner Electrolyte Metab 1999;25:95-99.
33. Garibotto G, Sofia A, Valli A, Tarroni A, Di Martino M, Cappelli V, Aloisi F, Procopio V: Causes of hyperhomocysteinemia in patients with chronic kidney diseases. Semin Nephrol 2006;26:3-7.
34. Norlund L, Grubb A, Fex G, Leksell H, Nilsson JE, Schenck H, Hultberg B: The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin Chem Lab Med 1998;36:175-178.
35. Friedman JA, Dwyer JT: Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Nutr Rev 1995;53:197-201.
36. Moustapha A, Gupta A, Robinson K, Arheart K, Jacobsen DW, Schreiber MJ, Dennis VW: Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 1999;55:1470-1475.
37. Garibotto G, Sofia A, Saffioti S, Russo R, Deferrari G, Rossi D, Verzola D, Gandolfo MT, Sala MR: Interorgan exchange of aminothiols in humans. Am J Physiol Endocrinol Metab 2003;284:E757-E763.
38. Suliman ME, Qureshi AR, Bárány P, Stenvinkel P, Filho JC, Anderstam B, Heimbürger O, Lindholm B, Bergström J: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-1735.
39. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
40. Suliman ME, Stenvinkel P, Qureshi AR, Bárány P, Heimbürger O, Anderstam B, Alvestrand A, Lindholm B: Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis 2004;44:455-465.
41. Suliman ME, Stenvinkel P, Bárány P, Rashid Qureshi A, Lindholm B: Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. Semin Nephrol 2006;26:14-19.
42. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007;18:304-311.
43. Kalantar-Zadeh K: Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: what is next? Semin Dial 2005;18:365-369.
44. Deussen A, Pexa A, Loncar R, Stehr SN: Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity? Clin Chem Lab Med 2005;43:1007-1010.
45. Chen YF, Li PL, Zou AP: Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002;106:1275-1281.
46. Vallon V, Mühlbauer B, Osswald H: Adenosine and kidney function. Physiol Rev 2006;86:901-940.
47. Cramer DV, Wu GD, Chapman FA, Marboe C, Salomon DR: 2- Chlorodeoxyadenosine in combination with cyclosporine inhibits the development of transplant arteriosclerosis in rat cardiac allografts. Transplant Proc 1997;29:616.
48. Sciotti VM, Van Wylen DG: Attenuation of ischemia-induced extracellular adenosine accumulation by homocysteine. J Cereb Blood Flow Metab 1993;13:208-213.
49. Zou CG, Banerjee R: Homocysteine and redox signaling. Antioxid Redox Signal 2005;7:547-559.
50. Handy DE, Zhang Y, Loscalzo J: Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 2005;280:15518-15525.
51. Lu SC: Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J 1999;13:1169-1183.
52. Mosharov E, Cranford MR, Banerjee R: The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry 2000;39:13005-13011.
53. Zou CG, Banerjee R: Tumor necrosis factor-alpha-induced targeted proteolysis of cystathionine beta-synthase modulates redox homeostasis. J Biol Chem 2003;278:16802-16808.
54. Cai H, Griendling KK, Harrison DG: The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003;24:471-478.
55. Geiszt M, Kopp JB, Varnai P, Leto TL: Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 2000;97:8010-8014.
56. Gill PS, Wilcox CS: NADPH oxidases in the kidney. Antioxid Redox Signal 2006;8:1597-1607.
57. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
58. Zou AP, Li N, Cowley AW Jr: Production and actions of superoxide in the renal medulla. Hypertension 2001;37(2 Pt 2):547-553.
59. Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313.
60. Hordijk PL: Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006;98:453-462.
61. Takeya R, Sumimoto H: Regulation of novel superoxide-producing NAD(P)H oxidases. Antioxid Redox Signal 2006;8:1523-1532.
62. Shastry S, Ingram AJ, Scholey JW, James LR: Homocysteine induces mesangial cell apoptosis via activation of p38-mitogen-activated protein kinase. Kidney Int 2007;71:304-311.
63. Yi F, Zhang AY, Li N, Muh RW, Fillet M, Renert AF, Li PL: Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int 2006;70:88-96.
64. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ: Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000;275:29318-29323.
65. Yang ZZ, Zou AP: Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. Kidney Int 2003;63:1012-1020.
66. Yi F, Dos Santos EA, Xia M, Chen QZ, Li PL, Li N: Podocyte injury and glomerulosclerosis in hyperhomocysteinemic rats. Am J Nephrol 2007;27:262-268.
67. Yi F, Zhang AY, Janscha JL, Li PL, Zou AP: Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int 2004;66:1977-1987.